Relapsed Acute Lymphoblastic Leukemia (ALL) Active Not Recruiting Phase 1 / 2 Trials for Cyclophosphamide (DB00531)

Back to Relapsed Acute Lymphoblastic Leukemia (ALL)

Also known as: Acute Lymphoblastic Leukemia, in Relapse / Relapsed ALL / Relapsed Acute Lymphoblastic Leukemia / Acute, relapsed Lymphoblastic Leukemia

Indication	Status	Phase
DBCOND0069491 (Relapsed Acute Lymphoblastic Leukemia (ALL))	Active Not Recruiting	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03573700	Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia	Treatment	Coenzyme M (DB09110) Cyclophosphamide (DB00531) Fludarabine (DB01073)
NCT05192889	Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax	Treatment	Asparaginase Erwinia chrysanthemi (DB08886) Asparaginase Escherichia coli (DB00023) Blinatumomab (DB09052) Calaspargase pegol (DB14730) Cyclophosphamide (DB00531) Cytarabine (DB00987) Dasatinib (DB01254) Dexamethasone (DB01234) Etoposide (DB00773) Hydrocortisone (DB00741) Leucovorin (DB00650) Mercaptopurine (DB01033) Methotrexate (DB00563) Navitoclax (DB12340) Pegaspargase (DB00059) Venetoclax (DB11581) Vincristine (DB00541)